Trigen plan ahead as Tapp exits

Biopharmaceutical company Trigen is without a head of corporate comms after losing Ashley Tapp to Abchurch Communications.

Trigen, a private company with 25 staff across offices in London and Munich, specialises in cardiovascular drug discovery and development. It focuses on drugs which target thrombosis and atherosclerosis – the hardening or ‘furring’ of arteries.

In the medium term, the head of corporate comms role will be divided between Trigen finance director Barry Knight, CEO Sanjay Kakkar and a PR agency which the company refused to name. ‘We won’t need to replace him directly for the foreseeable future, we are in a quiet news period,’ said Knight.

Tapp worked for Trigen for three years. Before that he was at biotech, pharma and healthcare comms agency Noonan/Russo for five years. He joins Abchurch as an account director in the agency’s life sciences division, reporting to chief executive Julian Bosdet.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in